This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Imipenem (MK-0787) + Cilastatin (MK-0791)
Description: Primaxin is a combination of Imipenem (a carbapenem antibiotic) and cilastatin (a dehydropeptidase I inhibitor that blocks degradation of imipenem to a nephrotoxic metabolite in the kidneys).
Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity, and have a structure which renders them highly resistant to beta-lactamases. Members of this class exhibit good activity against methicillin-sensitive Staphylococcus aureus, streptococci, anaerobes, enteric Gram-(-) rods (including strains that produce extended spectrum beta lactamases), Pseudomonas, and Acinetobacter. Moderate activity is observed against enterococci, and relatively modest activity against methicillin-resistant S. aurus and penicillin-resistant streptococci.
Additional information available to subscribers only: